drugset / Trial / NCT00680043
Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease who are on dialysis and are not taking any treatment to increase their red blood cell production.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | epoetin alfa | Protein / enzyme biologic | 50 iu/kg | Intravenous |
| Subject | peginesatide | Peptide | 0.04 mg/kg | Intravenous |
| Subject | peginesatide | Peptide | 0.08 mg/kg | Intravenous |